メニュー戻る Poster-Presentations-Details

P32: Evaluation of the Clinical Impact of Rare Disease Scientific Responses Provided by Pfizer US Medical Information to Providers

Poster Presenter

Arianna Burton

Senior Manager, US Medical Affairs, Rare Disease
Pfizer Inc
United States

Objectives

•Assess the clinical impact of rare disease (RD) medical information (MI) provided by US MI to healthcare providers (HCPs) •Evaluate the effect of gamified survey elements on engagement, robustness of response and time to completion •Evaluate US MI customer satisfaction

Method

A 19-question survey was administered via email to HCPs who received information on a RD product from 05-01-2019 onward and also posted to the Pfizer MI website. Random assignment of gamified or traditional survey design was used. A net promoter score (NPS) assessed customer satisfaction.

Results

Analysis is ongoing, as of 12-20-2020, 46 HCPs attempted or completed the survey. Surveys were emailed to HCPs starting 10-20-2020 and posted to the Pfizer RD website starting 10-22-2020. Of the respondents, 19 identified as physicians, 8 as pharmacists, and 7 as an advanced prescribing practitioner. The most common reason for contacting MI regarding the RD product was to gather information to guide a treatment decision (11/20). Other top reasons were to obtain general information on the product (9/20), and to obtain information to update guidelines, formulary, or drug information resources (8/20). The majority gathered information for their own use (15/26), shared/discussed with a colleague (13/26), made a clinical or therapeutic decision related to the product (12/26), and shared the information with a patient or caregiver (9/26). When asked about preferred sources of RD medical information, Pfizer MI had the highest net preference following the review of published literature and prescribing information. Gamified respondents found the survey experience to be significantly more interesting than the traditional survey respondents.7/9 gamified respondents agreed that the amount of time to complete the survey was reasonable, compared to 9/14 traditional respondents, but there was no difference in actual time to completion. Two-thirds of completed responses took less than 10 minutes. The most in-survey drop-offs occurred during the MaxDiff exercise. Insufficient data is available, at the time of interim analysis, to conclusively evaluate the impact of gamification on completion time and response rates. However, there are no significant differences in the robustness of responses collected between gamified and traditional responses. As a result of the customer satisfaction NPS interim analysis, Pfizer’s reputation scored +52. Notably, as per market research, a “good” score ranged from score of 0 to 30, while a “great” score was between 30 to 70.

Conclusion

The results of the survey will be used to better understand how the clinical impact of Pfizer MI scientific responses can enable HCPs to make informed clinical decisions about a RD product. The interim analysis conducted, to obtain results, was done with a small sample size. Due to the small sample of survey respondents, interim analysis of the data can only provide directional guidance at this time.